Covaxin (688136.SH): The clinical trial registration application for GB10 injection has been accepted.

Financial news app Zhitong reported that Kexing Pharmaceuticals (688136.SH) released an announcement. Recently, the company's wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. (referred to as "Shenzhen Kexing") received an administrative license document from the National Medical Products Administration (referred to as the "NMPA") titled "Acceptance Notice". The company's application for clinical trials of "GB10 Injection" has been accepted.